SOURCE: TomoTherapy

TomoTherapy

February 09, 2010 09:05 ET

TomoTherapy Enters Australian Market With Purchase by Royal Brisbane & Women's Hospital

Company Inks Distribution Agreement With Nucletron for Australia and New Zealand

MADISON, WI--(Marketwire - February 9, 2010) - TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, announced today that it is expanding into Australia and New Zealand. The company recently signed a distribution agreement with Nucletron Pty. Ltd. and was awarded a contract by Queensland Health to supply the first TomoTherapy® treatment system in Australia to Royal Brisbane & Women's Hospital.

"We are very pleased to be the first facility in Australia that will offer the advanced cancer treatment capabilities of the TomoTherapy system," said Dr. Roger Allison, director of cancer care services at Royal Brisbane & Women's Hospital. "We anticipate it will optimise our treatment for many patients with complex cancer problems."

Royal Brisbane & Women's Hospital purchased TomoTherapy's flagship Hi-Art® treatment system, which is a fully-integrated, ring gantry-based system that combines a CT scanner and linear accelerator for the delivery of image-guided, intensity-modulated radiation therapy (IG-IMRT). The TomoTherapy Hi-Art system enables development of sophisticated treatments plans for a wide range of cancer cases and offers unique helical radiation delivery capabilities that allow for precise tumor targeting from all angles around a patient. With imaging capabilities built into the TomoTherapy system, clinicians can acquire daily 3D CT images to ensure accurate delivery of radiation, minimizing damage to surrounding normal tissues and structures and potentially reducing side effects for patients.

"Until now, we have not had the integrated technology to deliver IMRT treatments to our patients," said Greg Rattray, assistant director of radiation therapy at Royal Brisbane & Women's Hospital. "With the installation of the TomoTherapy system, we will be able to advance our capabilities to the leading edge of IG-IMRT treatments. And we are confident that the integrated nature and ease-of-use of the TomoTherapy system will make for a very smooth transition."

Royal Brisbane & Women's Hospital expects to begin treating patients on the TomoTherapy system by the end of June 2010.

Distribution Partner
Nucletron Pty. Ltd. is TomoTherapy's exclusive distribution partner in Australia and New Zealand. "We are thrilled to be working with TomoTherapy to bring such a great technology to the people of Australia and New Zealand," said Peter Douglas, Nucletron's managing director. "We believe that there will be great demand for the TomoTherapy system in these countries, and with the superb technology, sales and support we receive from TomoTherapy, we are well positioned to meet that demand."

"The expansion of TomoTherapy's reach into Australia and New Zealand underscores the growing recognition that our IG-IMRT solution enables facilities to provide state-of-the-art care, compared to conventional solutions," said Frederick A. Robertson, MD, TomoTherapy's president and CEO. "Our relationship with Nucletron and first installation with Royal Brisbane Hospital, will allow us to showcase the benefits of our robust radiation therapy solution to a large, new market."

Informational Tour of Australia Set for February 22-26, 2010
TomoTherapy and Nucletron Pty. Ltd. will host a series of informational evenings in Australia, February 22-26, 2010. The sessions will include presentations from Dr. Florian Sterzing, radiation oncologist, University of Heidelberg, Germany, and June Dean, radiation therapist, Addenbrooke's Cancer Center, Cambridge, UK. Please visit http://www.tomotherapy.com/news/events/australia_tour_2010 for details.

About Nucletron
Nucletron is a knowledge-based leader in radiation oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams -- reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians. For more information, visit http://www.nucletron.com.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its flagship Hi-Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi-Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Contact Information

  • Investor Contact:
    Thomas E. Powell
    Chief Financial Officer
    608.824.2800
    Email Contact

    Media Contacts:

    Kevin O'Malley
    Manager, Corporate Communications
    608.824.3384
    Email Contact

    Susan Lehman
    Rockpoint Public Relations
    510.832.6006
    Email Contact